// App-Quantinova.ai

: Health-related quality of life (HRQoL) impact of lenvatinib (len) plus pembrolizumab (pembro) versus len plus placebo (pbo) as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC): Phase 3 LEAP-002 study.

Researchers

Presenter

  • Josep M Llovet

Principal Investigators

  • Philippe Merle

  • Tim Meyer

  • Shukui Qin

  • Masafumi Ikeda

  • Ruocai Xu

  • Julien Edeline

  • Baek-Yeol Ryoo

  • Zhenggang Ren

  • Ann-Lii Cheng

  • Peter R Galle

  • Shuichi Kaneko

  • Hiromitsu Kumada

  • Shital Kamble

  • Josephine M Norquist

  • Kalgi Mody

  • Leonid Dubrovsky

  • Abby B. Siegel

  • Richard S. Finn

Medical Centers

  • Department of Gastroenterology, Graduate School of Medicine Kobe University, Kobe, Japan

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

  • Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan

  • University Medical Center Mainz, Mainz, Germany

  • Eisai Inc., Nutley, NJ

  • Department of Medical Oncology, Eugene Marquis Center, Rennes, France

  • Liver Cancer Institute & Zhong Shan Hospital, Fudan University, Shagnhai, China

  • HCL Hopital Croix-Rousse, Lyon, France

  • Merck & Co. Inc., Rahway, NJ

  • Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of (South), Korea

  • National Taiwan University Hospital, Taipei City, Taiwan

  • Department of Hematology, Toranomon Hospital, Tokyo, Japan

  • Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, IDIBAPS, Hospital Clinic Barcelona, University of Barcelona, Catalonia, Spain, Institució Catalana d’Estudis Avançats (ICREA), Barcelona, Spain

  • Department of Gastroenterology and Hepatology, Kinki University School of Medicine, Osaka-Sayama, Japan

  • Cancer Center of Jinling Hospital, Nanjing Chinese Medicine University, Nanjing, China

  • UCLA Medical Center, Santa Monica, CA

  • Hunan Cancer Hospital, Changsha, China

Locations

  • United Kingdom

  • Republic of South Korea

  • United States

  • China

  • Spain

  • Taiwan

  • Germany

  • Japan

  • France

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Liver cancer

Biomarkers

  • N/A

Drug/Treatment

  • Pembrolizumab

  • Lenvatinib

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • III

Study Id's

  • NCT03713593

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved